TCM
ITCI

TimesSquare Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

TimesSquare Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-840,269
Closed -$70.2M – 163
2024
Q4 		$70.2M Buy
840,269
+402,186
+92% +$33M 1.02% 32
2024
Q3 		$32.1M Buy
438,083
+26,600
+6% +$2M 0.48% 84
2024
Q2 		$28.2M Buy
411,483
+28,272
+7% +$1.96M 0.44% 90
2024
Q1 		$26.5M Sell
383,211
-113,139
-23% -$7.78M 0.39% 100
2023
Q4 		$35.5M Sell
496,350
-5,275
-1% -$303K 0.52% 83
2023
Q3 		$26.1M Buy
501,625
+48,250
+11% +$2.81M 0.41% 100
2023
Q2 		$28.7M Sell
453,375
-57,700
-11% -$3.6M 0.41% 105
2023
Q1 		$27.7M Sell
511,075
-196,925
-28% -$9.52M 0.4% 108
2022
Q4 		$37.5M Sell
708,000
-177,510
-20% -$8.9M 0.53% 90
2022
Q3 		$41.2M Buy
885,510
+84,672
+11% +$4.42M 0.57% 78
2022
Q2 		$45.7M Sell
800,838
-76,190
-9% -$4.32M 0.64% 64
2022
Q1 		$53.7M Sell
877,028
-466,937
-35% -$24.2M 0.6% 72
2021
Q4 		$70.3M Sell
1,343,965
-374,700
-22% -$15.7M 0.62% 63
2021
Q3 		$64.1M Buy
1,718,665
+565,285
+49% +$19.7M 0.56% 70
2021
Q2 		$47.1M Sell
1,153,380
-73,900
-6% -$2.73M 0.39% 112
2021
Q1 		$41.6M Buy
1,227,280
+338,080
+38% +$11.7M 0.36% 124
2020
Q4 		$28.3M Sell
889,200
-13,300
-1% -$350K 0.23% 158
2020
Q3 		$23.2M Buy
+902,500
New +$20.6M 0.22% 167
2017
Q1 		– Sell
-1,534,938
Closed -$23.2M – 264
2016
Q4 		$23.2M Sell
1,534,938
-221,637
-13% -$3.13M 0.16% 203
2016
Q3 		$26.8M Buy
1,756,575
+136,700
+8% +$5.53M 0.17% 194
2016
Q2 		$62.9M Buy
1,619,875
+95,500
+6% +$3.43M 0.42% 97
2016
Q1 		$42.4M Buy
1,524,375
+205,955
+16% +$6.86M 0.28% 135
2015
Q4 		$70.9M Buy
1,318,420
+218,420
+20% +$11M 0.45% 86
2015
Q3 		$44M Buy
+1,100,000
New +$35.9M 0.28% 136

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TimesSquare Capital Management's ITCI Position: Q1 2025 in Review

TimesSquare Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 840,269 shares — an estimated $70.2M sold.

TimesSquare Capital Management first reported a position in ITCI in Q3 2015 and held it in 24 quarters. The position peaked at $70.9M in Q4 2015. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • TimesSquare Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • TimesSquare Capital Management sold 840,269 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $70.2M.
  • TimesSquare Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 24 quarters.
  • TimesSquare Capital Management's Intra-Cellular Therapies Inc. position peaked at $70.9M in Q4 2015.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on TimesSquare Capital Management's 13F filing for Q1 2025, filed 2 May 2025.